RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/33615517http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/33615517http://www.w3.org/2000/01/rdf-schema#comment"5-Fluorouracil (5-FU) is a widely used chemotherapeutic drug, but the mechanisms underlying 5-FU efficacy in immunocompetent hosts in vivo remain largely elusive. Through modeling 5-FU response of murine colon and melanoma tumors, we report that effective reduction of tumor burden by 5-FU is dependent on anti-tumor immunity triggered by the activation of cancer-cell-intrinsic STING. While the loss of STING does not induce 5-FU resistance in vitro, effective 5-FU responsiveness in vivo requires cancer-cell-intrinsic cGAS, STING, and subsequent type I interferon (IFN) production, as well as IFN-sensing by bone-marrow-derived cells. In the absence of cancer-cell-intrinsic STING, a much higher dose of 5-FU is needed to reduce tumor burden. 5-FU treatment leads to increased intratumoral T cells, and T-cell depletion significantly reduces the efficacy of 5-FU in vivo. In human colorectal specimens, higher STING expression is associated with better survival and responsiveness to chemotherapy. Our results support a model in which 5-FU triggers cancer-cell-initiated anti-tumor immunity to reduce tumor burden, and our findings could be harnessed to improve therapeutic effectiveness and toxicity for colon and other cancers."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.org/dc/terms/identifier"doi:10.15252/embj.2020106065"xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/author"Lu J."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/author"Khan S."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/author"Lu Q."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/author"Wang Y."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/author"Tian J."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/author"Wang Q."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/author"Wu L."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/author"Yan Q."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/author"Zhang D."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/author"Fang D."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/author"Bosenberg M."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/author"Muzumdar M.D."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/author"Kurbatov V."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/date"2021"xsd:gYear
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/name"EMBO J"xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/pages"e106065"xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/title"5-Fluorouracil efficacy requires anti-tumor immunity triggered by cancer-cell-intrinsic STING."xsd:string
http://purl.uniprot.org/citations/33615517http://purl.uniprot.org/core/volume"40"xsd:string
http://purl.uniprot.org/citations/33615517http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/33615517
http://purl.uniprot.org/citations/33615517http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/33615517
http://purl.uniprot.org/uniprot/#_A0A125R9I3-mappedCitation-33615517http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33615517
http://purl.uniprot.org/uniprot/#_D3Z5R0-mappedCitation-33615517http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33615517